Björn Pasternak

Björn Pasternak

Principal Researcher | Docent
Visiting address: ,
Postal address: K2 Medicin, Solna, K2 KEP Askling Pasternak, 171 77 Stockholm
Part of:

About me

  • 2002-2007 MD, Linköping University, Sweden 2004-2008 PhD, Linköping University, Sweden 2009-2016 Postdoc and Researcher, Statens Serum Institut, Copenhagen, Denmark 2016- Senior/Principal Researcher, Karolinska Institutet 2017- Associate Professor (docent), Karolinska Institutet

Research

  • Thriving on substantial expertise in large-scale register studies of adverse drug effects, we have the overall objective of using high-quality epidemiology to help inform evidence-based decisions in clinical practice. We have ongoing research programs in pediatric pharmacoepidemiology
  • safety and effectiveness of new diabetes drugs
  • and the area of expedited assessment of current drug safety concerns. My team’s scope is not limited to one single disease entity or therapeutic area
  • rather, we are in a constant process of seeking out and addressing emerging drug safety concerns with implications for clinical practice. TEAM MEMBERS * Peter Ueda [1], MD, PhD, assistant professor * Viktor Wintzell [2], PhD, coordinator/statistician * Henrik Svanström [3], PhD, senior statistician * Arvid Engström [4], MD, PhD-student * Carl-Emil Lim [5], MD/PhD-student * Laura Pazzagli [7], PhD, research specialist * Paulina J PhD, postdoc OUR RESEARCH IS AND HAS BEEN FUNDED BY * Swedish Research Council * Karolinska Institutet Faculty Funded Consolidator Grant * Swedish Cancer Society * Swedish Heart-Lung Foundation * Thrasher Research Foundation * Novo Nordisk Foundation * Nordic Cancer Union * Swedish Diabetes Foundation * Strategic Research Area Epidemiology (SfoEpi) at Karolinska Institutet * Karolinska Institutet Foundations and Funds * Stiftelsen Frimurare Barnhuset * Alzheimerfonden * Dr Margaretha Nilsson Stiftelse för Medicinsk Forskning * Åke Wibergs Stiftelse * Magnus Bergvalls Stiftelse SELECTED PUBLICATIONS Wintzell V, Svanström H, *Pasternak B. *Selection of comparator group in observational drug safety studies: alternatives to the active comparator new user design. *Epidemiology* 2022 *Pasternak B*, Wintzell V, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. *BMJ* 2020 *Pasternak B, *Ueda P, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Wintzell V, Melbye M, Svanström H. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. *BMJ *2019 Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, *Pasternak B. *Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. *Lancet Diabetes Endocrinol* 2019 Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, *Pasternak B. *Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. *BMJ* 2018 *Pasternak B, *Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. *BMJ* 2018 Scheller NM, *Pasternak B*, Mølgaard-Nielsen D, Svanström H, Hviid A. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes. *New England Journal of Medicine* 2017 Molgaard-Nielsen D, Svanstrom H, Melbye M, Hviid A, *Pasternak B*. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. *JAMA* 2016 Scheller NM, Svanstrom H, *Pasternak B*, Arnheim-dahlstrom L, Sundstrom K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. *JAMA* 2015 Scheller NM, *Pasternak B*, Svanstrom H, Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. *JAMA* 2014 Nyboe Andersen N, *Pasternak B*, Basit S, Andersson M, Svanstrom H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. *JAMA* 2014 Feenstra B, *Pasternak B*, Geller F, Carstensen L, Wang T, Huang F, et al. Common variants associated with general and MMR vaccine-related febrile seizures. *Nature genetics* 2014 Molgaard-Nielsen D, *Pasternak B*, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. *New England Journal of Medicine* 2013 Hviid A, Melbye M, *Pasternak B*. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. *New England Journal of Medicine* 2013 Svanstrom H, *Pasternak B*, Hviid A. Use of azithromycin and death from cardiovascular causes. *New England Journal of Medicine* 2013 *Pasternak B*, Svanstrom H, Melbye M, Hviid A. Association between oral fluoroquinolone use and retinal detachment. *JAMA* 2013 *Pasternak B*, Svanstrom H, Molgaard-nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. *JAMA* 2013 *Pasternak B*, Svanstrom H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. *New England Journal of Medicine* 2013 *Pasternak B*, Svanstrom H, Molgaard-nielsen D, Krause Tg, Emborg Hd, Melbye M, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. *JAMA* 2012 *Pasternak B*, Svanstrom H, Molgaard-nielsen D, Krause Tg, Emborg Hd, Melbye M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. *BMJ* 2012 Svanstrom H, *Pasternak B*, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. *JAMA* 2012 *Pasternak B*, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. *JAMA* 2010 *Pasternak B*, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. *New England Journal of Medicine* 2010 [1] http://ki.se/en/people/petjak [2] http://ki.se/en/people/viktwi [3] https://ki.se/en/people/henrsv [4] https://staff.ki.se/people/arengs [5] https://staff.ki.se/people/carlemil-lim [7] https://staff.ki.se/people/laura-pazzagli

Articles

All other publications

Employments

  • Principal Researcher, Department of Medicine, Karolinska Institutet, 2022-

Degrees and Education

  • Docent, Karolinska Institutet, 2017

News from KI

Events from KI